Rise of menopause discourse

Menopause is a multifaceted midlife transition with profound implications for physical and psychological health [1, 2]. While clinical focus has traditionally centred on vasomotor and genitourinary symptoms treated via hormone replacement therapy (HRT) [3], the psychological dimensions, including mood disorders, anxiety, and cognitive changes, remain historically underrecognised [1, 4]. These life-altering effects are not universal; they emerge from a complex interplay of biological, psychosocial, and environmental factors rather than endocrine status alone [4, 5].

Recent evidence, including a 2024 systematic review and meta-analysis of over 9000 women, confirms that the perimenopausal transition carries a significantly elevated risk for depressive symptoms compared to the premenopausal phase [6]. Notably, this vulnerability appears specific to the transition itself, as the risk is not similarly elevated in postmenopause [6]. These psychological symptoms, ranging from irritability to sleep disruption, arise as fluctuating ovarian hormones modulate serotonergic and GABAergic systems, interacting with life stressors to impact affective regulation [5, 7, 8].

Despite these findings, public and clinical awareness remains deficient [1]. A 2026 YouGov poll for the Royal College of Psychiatrists revealed that only 28% of women recognise the link between menopause and mental illness, while three-quarters remain unaware that the transition can trigger new psychiatric symptoms [9]. This pervasive lack of awareness extends beyond lay populations, as surveys of clinician preparedness are also concerning, with many healthcare providers reporting minimal formal training in menopause-related mental health [1, 4]. These knowledge gaps among both patients and providers often lead to misdiagnosis and delayed care [9].

The surge in media coverage, advocacy, and workplace policy has successfully destigmatised menopause [10, 11], yet it has also fostered polarised narratives that often overlook the multifactorial nature of this transition [12, 13]. Public discourse frequently fluctuates between over-medicalising the transition as a universal biological deficiency requiring pharmaceutical intervention [14–16] and dismissing psychological symptoms as merely normative consequences of aging or life stress [17, 18]. These reductive portrayals risk distorting clinical decision-making and shaping narrow expectations [19, 20], ultimately obscuring the complex, individual realities of the menopausal experience [13, 21, 22].

This narrative aims to bridge the gap between clinical research and the prevailing public narrative by integrating neurobiological evidence of menopausal mood changes with epidemiological findings. We advocate for a nuanced, biopsychosocial approach that moves beyond oversimplified labels and more accurately reflects the complexity of women’s mental health during midlife.

Neuroendocrine basis of mood changes in menopause

The climacteric is not merely a reproductive event but a neuroendocrine transition that reshapes hormonal patterns and exerts profound effects on the brain [22, 23]. This is well established in both clinical and experimental literature, where the fluctuation and eventually decline of ovarian steroids is linked to changes in central nervous system function affecting mood, cognition, and neural regulation [24]. At the core of these changes are oestrogen and progesterone, steroids that exert broad influences on neurotransmitter systems, neuroplasticity, and neuroendocrine networks beyond their roles in reproduction [25–28].

Oestrogen modulates major neurotransmitter systems, including serotonin, dopamine, and γ-aminobutyric acid (GABA) [8, 28], which play key roles in affective balance [26]. For example, oestrogen enhances serotonergic function by increasing the synthesis of tryptophan hydroxylase [28], regulating receptor expression [23], and facilitating neurotransmission in mood-related regions like the hippocampus and prefrontal cortex [24, 27]. These effects explain why oestrogen fluctuations during perimenopause – rising and falling unpredictably before stabilising at a low plateau – are associated with emotional instability. Similarly, oestrogen interacts with dopaminergic pathways, influencing synthesis and receptor sensitivity in circuits underlying reward and executive function [28]. In parallel, oestrogen modulates inhibitory processes via GABAergic systems, while its loss can lead to reduced inhibitory tone and increased neuronal excitability, potentially contributing to anxiety [24, 28].

Progesterone also interacts with brain chemistry [28]. Although often overshadowed, progesterone and its neuroactive metabolites influence mood through modulation of monoamine oxidase (MAO), an enzyme that degrades serotonin and dopamine [28]. Elevated MAO activity, influenced by progesterone, may reduce the availability of mood stabilising neurotransmitters, further complicating the neurochemical landscape during the transition [28].

Beyond neurotransmission, menopause shifts the balance of neural circuits involved in affect regulation [26]. Neuroimaging studies document structural and functional brain changes across menopause stages exceeding chronological aging alone, with evidence of altered connectivity and metabolic changes in the prefrontal cortex, hippocampus, and temporal lobes [26, 29]. These neurobiological observations support clinical patterns where women in perimenopause, rather than postmenopause, exhibit higher rates of depressive symptoms compared with premenopausal women [30].

While hormonal changes provide a framework for understanding mood susceptibility, they do not act in isolation [26]. Individual differences in genetic predisposition, psychiatric history, stress exposure, and sociocultural context interact with neuroendocrine mechanisms to determine clinical outcomes [30, 31]. Fluctuating hormone levels may lower thresholds for symptoms in vulnerable individuals but are neither necessary nor sufficient to cause mood disorders in every woman [30, 32].

Therefore, the neuroendocrine basis of mood changes in menopause reflects a dynamic interplay between changing hormone profiles and brain systems that regulate emotion, cognition, and arousal. Understanding these biological underpinnings is essential but must be integrated with psychosocial and environmental factors to provide a complete picture of menopause-related mental health.

Beyond mood regulation, the menopausal transition is frequently characterized by cognitive complaints, often described by patients as “brain fog,” including perceived difficulties with memory and verbal fluency [25, 29]. While oestrogen’s role in maintaining cognitive circuitry is well documented [23, 26], research reveals a notable paradox: women’s subjective reports of cognitive decline often do not correlate with objective neuropsychological test results [33]. Recent evidence suggests that these perceived difficulties are more closely associated with mood disturbances, sleep fragmentation, and vasomotor “domino effects” than with actual neurological impairment [33–36]. This distinction is vital for clinical management, as subjective “brain fog” may serve as a clinical proxy for underlying affective instability or physical symptom burden [1, 37].

Evidence linking menopause and psychiatric symptoms

The prevailing consensus in psychiatric literature and longitudinal population surveys challenges the historical medicalisation of menopause, specifically refuting the existence of a universal “menopause-induced” psychiatric disorder [38]. Data indicate that over 85% of women navigate the menopausal transition without clinical mood disturbances, and overall rates of depression frequently decline during middle age [39, 40]. The abandonment of the “involutional melancholia” construct underscores a shift toward viewing menopausal mental health through a biopsychosocial lens, where psychological distress is more often attributed to concurrent life events or cultural stigmas rather than intrinsic hormonal deficiency [41].

However, while menopause is not a primary driver of mental illness for the general population, a distinct “vulnerable” subgroup, that is often identified by a history of premenstrual syndrome or prior depressive episodes, exhibits a heightened sensitivity to the fluctuating perimenopausal hormonal milieu [42–44]. A critical factor in the decline of quality of life for this susceptible population is the “domino effect” of vasomotor symptoms [45, 46]. Chronic nocturnal hot flashes and night sweats lead to significant sleep fragmentation, which is a known independent risk factor for the development of depressive symptoms [47, 48].

While large-scale trials like the Women’s Health Initiative initially reported negligible improvements in quality of life with HRT, these findings were likely confounded by the inclusion of older, asymptomatic participants and the use of insensitive, generic measurement tools [2, 49–51]. In contrast, the WISDOM trial demonstrated that for symptomatic women, HRT provides statistically significant improvements in sleep quality and emotional well-being [52]. This suggests that the therapeutic benefit of oestrogen in this context is largely indirect: by stabilising thermoregulation and restoring sleep architecture, HRT mitigates the secondary psychological erosion that occurs during the menopausal transition [35, 37].

Prospective cohort data, including the Penn Ovarian Aging and Study of Women’s Health Across the Nation (SWAN), confirm that individual vulnerability interacts significantly with reproductive aging [31, 53, 54]. Women with a prior history of depression or an earlier onset of the menopausal transition exhibit heightened sensitivity to the fluctuating hormonal milieu, with risk often co-occurring with vasomotor-driven sleep fragmentation [37, 54–57]. This suggests that the timing and duration of hormonal instability – rather than low steady-state levels alone – contribute to mood vulnerability [31, 54, 55].

Despite consistent reporting of mood symptoms, the effect sizes when comparing menopausal status to psychiatric diagnoses are modest [45, 58]. A meta-analysis of observational studies concluded that while perimenopause is associated with increased odds of depressive symptoms, the association attenuates when controlling for life stressors, social support, and prior mental health history [59]. Indeed, some large population studies reported no significant difference in clinically diagnosed major depressive disorder when comparing pre and postmenopausal women after rigorous adjustment for confounders [60, 61]. These findings challenge simplistic interpretations that menopause universally precipitates major psychiatric illness and instead support a model in which multiple biological and psychosocial factors converge.

Diagnostic complexity of midlife mood disorders

Midlife represents a unique period in women’s mental health, marked by the convergence of hormonal fluctuations, psychosocial transitions, and cumulative life stressors, all of which complicate the recognition and diagnosis of mood disorders [62, 63]. Clinicians frequently face challenges in distinguishing between depressive or anxiety symptoms driven primarily by reproductive aging and those arising from preexisting psychiatric vulnerabilities [58]. This complexity is amplified by the overlapping symptomatology of menopause-related physiological changes, such as sleep disruption, fatigue, and cognitive complaints, and classical psychiatric presentations, leading to potential misclassification or underdiagnosis [37, 58].

Perimenopause and early postmenopause are characterised by erratic oestrogen and progesterone patterns, which influence neurotransmitter systems implicated in mood regulation, including serotonergic, dopaminergic, and GABAergic pathways [8, 31, 63]. These neuroendocrine changes can precipitate transient emotional lability, irritability, and low mood, which may mimic or exacerbate depressive disorders [8, 31]. Longitudinal evidence suggests that the timing and magnitude of hormonal shifts, rather than absolute hormone levels, are critical determinants of vulnerability, particularly in women with a history of mood disorders [31, 54].

Epidemiological studies underscore that the risk of new-onset depression in midlife is not uniform but concentrated among women with previous depressive episodes, severe vasomotor symptoms, or significant life stressors, highlighting the interaction between biological predisposition and psychosocial context [53, 64]. Consequently, a perimenopausal woman presenting with insomnia, fatigue, and low mood may be evaluated simultaneously for major depressive disorder, generalised anxiety disorder, sleep disorder, or menopausal transition-related affective changes [37, 58, 65]. This diagnostic overlap challenges the conventional psychiatric nosology and often necessitates a multi-domain assessment, incorporating gynaecologic, endocrinologic, and psychosocial perspectives [13, 16, 20, 61, 66, 67].

Clinical ambiguity is compounded by system-level factors. Mental health services may lack specific protocols for midlife women, while primary care clinicians often attribute mood complaints to “normal aging” or psychosocial stress rather than underlying endocrine changes, resulting in fragmented care [58, 68, 69]. Moreover, variability in symptom reporting across cultures, socioeconomic strata, and ethnic groups may skew clinical interpretation, as women may emphasise somatic complaints while underreporting affective symptoms due to stigma or cultural expectations [47, 48, 70].

From a research perspective, heterogeneity in study populations, definitions of menopause, and mood measurement tools further complicates the clinical translation of findings [16, 47, 49, 55, 67]. Randomised trials on hormone therapy for depression often exclude women with comorbidities, while observational studies may confound hormone levels with concurrent treatments or lifestyle factors, limiting generalisability [58, 63, 71]. This evidence gap reinforces the need for careful individualised assessment, integrating longitudinal history, hormonal profiles, psychosocial context, and risk factors for psychiatric illness.

Menopause in contemporary public discourse

Over the last two decades, menopause has emerged from clinical obscurity to occupy a prominent place in public dialogue [16, 70, 72], a shift increasingly characterised as the “menopausal turn” in the media and culture [10]. This newfound visibility has been fuelled by exponential media coverage [73, 74], wellness campaigns [75, 76], and intensive social media engagement [77, 78]. This rise in visibility has been double-edged: on one hand, it has helped reduce stigma and encourage open discussion about midlife health [12, 79]. On the other hand, it has produced a fragmented, market-driven narrative that prioritizes engagement and visibility over the accurate representation of women’s lived experiences [48, 80]. The proliferation of commercial interests in this space, ranging from dietary supplements and “hormone-free” alternatives to luxury wellness retreats, demonstrates how menopause has become commodified, often leveraging anxieties about aging, productivity, and desirability [76, 81, 82].

Social media platforms and wellness influencers contribute significantly to shaping perceptions of menopause [77, 78], frequently emphasising a narrow set of symptoms such as hot flashes, weight gain, or sexual health concerns [75, 82] while marginalising other clinically relevant domains [48, 83], including neuropsychiatric, cognitive, and cardiovascular aspects [29, 84]. This selective framing encourages women to interpret a broad range of midlife changes, like fatigue, mood swings, and sleep disturbances, primarily through a menopause lens, sometimes delaying recognition and treatment of treatable conditions like depression [31, 58], thyroid dysfunction [2], or metabolic disorders [84]. At the same time, the overemphasis on marketed solutions can inflate expectations regarding the efficacy of hormone therapy, off-label supplements [76, 85], or lifestyle products, creating a disconnect between perceived and actual clinical benefit [80, 82].

Political agendas intersect deeply with these commercial and media-driven narratives [16, 86]. Advocacy for workplace equity [79, 87, 88], anti-age discrimination [89, 90], or flexible employment policies [90, 91] occasionally invokes menopause experiences to bolster public campaigns [74, 92]. While these efforts aim to address systemic gender disparities, they may unintentionally conflate social messaging with medical realities [58, 70], simplifying or generalising complex individual experiences to serve broader policy objectives [5, 70, 83, 86]. In parallel, health systems often underprioritize menopause-specific care, in part due to political sensitivities, fragmented clinical guidelines, and inconsistent provider training [67, 69], leaving women with unmet clinical needs despite increased public awareness [56, 69, 80].

Evidence from sociological and media studies indicates that these dynamics are not neutral [72, 83]. Narratives about menopause in public discourse often reflect societal anxieties regarding aging, productivity, and gender roles, emphasising personal struggle over public health implications [5, 75, 93]. Consequently, research funding, guideline development, and clinical resources for midlife women have historically lagged behind other areas of women’s health [68]. Awareness campaigns and commercial initiatives, while well-intentioned in some cases [92], frequently fail to translate visibility into evidence-based interventions that address mental health, cardiovascular risk, sleep quality, and overall midlife wellbeing [5, 73, 94].

Bridging public discourse and clinical reality

While the visibility of menopause in media and public discourse has generated awareness and reduced stigma, it has also created a cultural lens through which women interpret a wide array of midlife experiences, including mood disturbances, sleep disruption, and cognitive changes [37, 54]. Sociocultural framing often emphasises simplified narratives – hot flashes, weight gain, or sexual dysfunction – which can obscure the multifactorial nature of menopausal health and the complex interplay of neuroendocrine, psychological, and social factors [37, 48]. Consequently, women may present to healthcare providers with expectations shaped more by marketed or socially amplified narratives than by their individual clinical needs, creating potential mismatches between perceived symptoms and underlying physiological or psychiatric conditions [13, 16, 63].

Evidence suggests that the neuroendocrine transitions of menopause – particularly fluctuations in oestradiol, progesterone, and their metabolites – can modulate neurotransmitter systems implicated in mood regulation, such as serotonin, dopamine, and GABA [56, 74]. These hormonal shifts may heighten vulnerability to depressive and anxiety symptoms, exacerbate sleep disturbances, and influence cognitive processing [55, 76, 78]. Yet, public discourse often fails to capture these nuances, framing mood changes primarily as personal or lifestyle challenges rather than biological phenomena with measurable clinical impact [93, 95]. This disconnection between public understanding and clinical evidence can result in underrecognition of midlife psychiatric conditions, misattribution of symptoms, or delayed intervention, reinforcing gaps in care [29, 96].

The commercialised portrayal of menopause further amplifies these challenges [29, 58, 72]. Marketing campaigns promoting supplements, “hormone-free” alternatives, or wellness programs frequently imply quick or universally effective solutions for mood, sleep, or cognitive complaints [58, 97, 98]. While these products may offer subjective benefit to some, they rarely address underlying neuroendocrine mechanisms or comorbid conditions and can generate unrealistic expectations regarding symptom resolution [46, 73, 81]. Moreover, media and social narratives can create a self-reinforcing loop: women who internalize these messages may misinterpret transient or unrelated symptoms as menopause-related, leading to unnecessary anxiety or inappropriate self-treatment.

Healthcare providers must navigate these culturally shaped expectations while grounding care in evidence-based understanding of menopausal biology. Awareness of public narratives is essential for clinicians to contextualize patient-reported symptoms, identify possible misattribution, and distinguish u6 from psychiatric, metabolic, or somatic disorders [97, 98]. Furthermore, recognising the influence of sociopolitical and commercial factors on symptom interpretation underscores the importance of integrating psychosocial assessment and patient education into clinical encounters [46, 99]. By bridging the gap between popular discourse and physiological evidence, clinicians can support women in receiving individualised, comprehensive care that addresses both subjective experiences and objective health risks [35, 49].

Multifactorial determinants of midlife mood symptoms

Midlife women’s experiences of mood disturbance are inherently complex, shaped by the intersection of biological, psychological, social, and cultural factors [54, 73, 100]. While endocrine changes across the menopausal transition can influence affective regulation, they do not operate in isolation; nor do they act as a uniform trigger for clinically significant mood disorders [52, 56]. Rather, emerging evidence shows that the development, presentation, and clinical trajectory of depression and anxiety in midlife are multifactorial [74, 80], and that interpreting these symptoms within narrow or monocausal frameworks – hormonal vs. psychiatric – often leads to diagnostic ambiguity and suboptimal care [76, 78].

Large longitudinal studies such as the SWAN have repeatedly demonstrated that perimenopausal women report higher levels of depressive and anxiety symptoms compared with premenopausal women, even when adjusting for age and sociodemographic factors [101]. However, absolute rates of major depressive disorder (i.e., meeting the Diagnostic and Statistical Manual of Mental Disorders, 5^th ed., text revision criteria) do not uniformly increase solely because of menopausal status [16]. Notably, women with prior histories of depression or anxiety, those experiencing severe vasomotor or sleep symptoms, and those coping with high levels of psychosocial stress exhibit the greatest vulnerability to midlife mood changes [77, 81, 80]. This highlights that predisposition and context matter at least as much as endocrine change.

The clinical presentation is further complicated by symptom overlap [48, 63]. Sleep disruption, fatigue, diminished concentration, and irritability – common during perimenopause – are also core features of depressive and anxiety disorders [2, 29]. This overlap frequently leads to differential diagnostic challenges in which the same symptom cluster may be variously attributed to menopause, depression, stress, or somatic disorders such as thyroid dysfunction or anaemia [2]. For example, women presenting with poor concentration and low mood might be diagnosed with major depressive disorder, yet the same features could reflect the neurophysiological impact of disrupted sleep architecture common in perimenopause [35]. Likewise, anxiety and irritability may be interpreted as personality traits or life stress reactions unless careful history and screening tools differentiate them from affective disorders.

Standardized diagnostic instruments, such as the Patient Health Questionnaire (PHQ-9) and the Generalised Anxiety Disorder Scale, remain the cornerstone of rapid clinical screening in midlife [78, 102]. However, clinicians must remain cognizant that somatic menopausal symptoms can sometimes inflate these scores [103]. For a more comprehensive psychiatric evaluation that distinguishes more clearly between affective and somatic dimensions of midlife depression, tools such as the Beck Depression Inventory may be considered as more representative of the formal diagnostic process [33].

Clinician interpretation is also influenced by training and specialty orientation [2, 16]. Primary care physicians may underrecognise psychiatric symptoms in midlife women, attributing them to “normal aging” or psychosocial stress rather than evaluating for mood disorders [73]. Psychiatrists, conversely, may emphasise psychiatric diagnoses without fully considering endocrine contributions or the temporal patterning of symptoms around the menopausal transition [78]. These disciplinary lenses shape assessment and treatment, potentially leading to fragmented care.

Finally, cultural and social context can influence both symptom expression and help seeking behaviour [73, 93]. Women from different backgrounds may emphasise somatic discomfort over emotional distress due to stigma or cultural expectations, affecting how disorders are recognised and addressed clinically [81]. Thus, culturally sensitive assessment frameworks are essential.

Diagnostic attribution bias across specialties

The clinical management of midlife mood disorders is profoundly shaped by subtle, often unrecognised biases in diagnostic attribution [31]. These biases emerge when clinicians preferentially attribute symptoms to either hormonal transitions or psychiatric pathology based on training, specialty norms, or systemic pressures [45, 59]. This is particularly salient in menopause, where overlapping somatic and affective symptoms blur traditional diagnostic boundaries [30, 37].

Primary care physicians often emphasise endocrine explanations, framing fatigue or low mood as expected consequences of the menopausal transition [13, 56]. While this can normalize experiences, it may lead to the underrecognition of depressive or anxiety disorders that warrant evidence-based treatment [55]. Conversely, mental health specialists may be more inclined to label these same symptoms as psychiatric, attributing them to depression or anxiety, without systematically considering the temporal correlation with perimenopausal hormonal fluctuations [53, 96]. This divergence illustrates the “disciplinary lens effect,” where a clinician’s background dictates symptom interpretation [58, 97].

Specialty-related biases are further compounded by health system frameworks and societal expectations [46, 98, 99]. In many contexts, insurance reimbursement structures prioritize specific psychiatric interventions over integrative midlife care, incentivising clinicians to align diagnoses with funded categories [35, 49]. Such systemic pressures inadvertently reinforce diagnostic simplifications, where complex presentations are dichotomised into “hormonal” or “psychiatric” rather than addressed through holistic evaluation [100].

Cultural narratives also influence attribution. Women increasingly engage with social media campaigns and wellness blogs that reinforce specific interpretations of menopause [73, 78, 93]. These narratives may suggest that mood symptoms are either inherently “normal” for midlife or, alternatively, entirely pathological [77, 81]. Patients’ own expectations, informed by these messages, can shape how they describe symptoms, potentially attenuating or amplifying certain complaints during consultation [29, 72, 101].

Importantly, misattribution has tangible consequences for patient outcomes [97]. It can lead to delayed diagnosis or fragmented care; for instance, women may receive hormone therapy when psychiatric evaluation is warranted, or antidepressants without addressing underlying endocrine triggers [52, 80]. Furthermore, persistent misattribution can exacerbate feelings of invalidation and undermine trust in healthcare systems [8, 70]. Interdisciplinary frameworks that integrate gynaecological and psychiatric perspectives are therefore critical to mitigate these biases.

Implications for clinical care

Effective management requires clinicians to navigate complex biological and social terrains while ensuring care remains patient-centred and evidence-based [5, 16, 73].

First, comprehensive assessment is essential. Clinicians should systematically evaluate mood, cognition, sleep, and vasomotor symptoms, contextualising them within the reproductive stage [31, 59]. Standardised screening tools like the PHQ-9, alongside detailed reproductive histories, aid in differentiating primary psychiatric disorders from perimenopausal transition-related symptoms [13]. Consideration of comorbid conditions – including thyroid disease and sleep apnoea – is equally vital, as these often mimic menopausal mood changes [49, 100].

Second, integrated, interdisciplinary approaches optimize outcomes. Collaboration between primary care, gynaecology, and psychiatry enables a holistic view of the patient [53, 58]. Evidence supports that multi-domain interventions, combining hormone therapy where appropriate with cognitive-behavioural strategies and lifestyle modification, are more effective than single-modality treatments [55, 56].

Third, shared decision-making and patient education are critical. Clinicians should transparently discuss the benefits and uncertainties of various therapies [55]. Clear communication grounded in evidence helps reconcile patient expectations with clinical reality and prevents over- or undertreatment [79, 86].

Fourth, system-level interventions are needed. Current structures often lack standardised pathways for midlife mental health [53, 58]. Policies that incentivise clinician training and integrate mental health screening into routine midlife visits can bridge the gap between public discourse and practice [92, 104]. Addressing disparities in access for marginalised populations remains a paramount necessity [84, 102].

Finally, remaining vigilant against diagnostic attribution bias is paramount [46, 97, 98]. Awareness of these biases, coupled with structured protocols, reduces misdiagnosis and enhances patient trust [31, 63]. Ultimately, a nuanced approach that bridges biomedical and psychosocial domains is necessary to meet the complex health needs of midlife women effectively.

Proposed actions for clinical practice

To address the current gaps in care, the following specific actions are proposed:

Conclusions

Menopause represents a complex intersection of biological, psychological, and sociocultural dimensions. Evidence underscores that midlife mood disturbances, cognitive changes, and psychosomatic symptoms cannot be attributed to hormonal fluctuations alone; they emerge from a dynamic interplay of neuroendocrine shifts, pre-existing psychiatric vulnerabilities, lifestyle factors, and broader social determinants [31, 105]. Clinical attention must therefore transcend reductionist explanations to prioritize individualised, evidence-based interventions.

Public and commercial discourse profoundly influences women’s perceptions and healthcare engagement [16]. While increased visibility has reduced stigma, it has also generated market-driven narratives emphasising youth and lifestyle optimisation over accurate health representations [76, 106]. Wellness industries and social media frequently promote selective symptoms, such as weight management, while underemphasising cognitive, cardiovascular, and mental health consequences with long-term implications [78]. This misalignment can create unrealistic expectations and delay evaluation of treatable conditions [73, 93].

Health systems are not immune to these influences; menopause-specific care remains underprioritised due to fragmented pathways, variable access, and historical underfunding [104]. Women often find themselves caught between clinical uncertainty and commercial messaging, highlighting the need for an integrated approach that bridges public discourse with evidence-based care.

A critical insight from this synthesis is the role of diagnostic attribution bias [97]. Clinicians across psychiatry, gynaecology, and primary care are susceptible to oversimplifying symptom causation, by either overemphasising hormonal shifts or solely blaming psychiatric disorders. Such biases can delay accurate diagnosis and erode patient trust [97]. Mitigating these tendencies requires structured assessment, interdisciplinary collaboration, and patient-centred communication.

Bridging the gap between clinical evidence and public discourse requires a multi-level strategy. Clinicians must integrate rigorous biomedical assessment with psychosocial context, while public messaging must strive for fidelity to women’s lived experiences. By navigating these intersecting domains, the medical community can move beyond superficial narratives to deliver care that is equitable, informed, and responsive to the holistic wellbeing of midlife women.